Rare inflammatory disease responds best to double inhibition, shows study
Hemophagocytic lymphohistiocytosis (HLH) is a rare and often aggressive syndrome of hyperactive inflammation with up to a 40% mortality rate. Scientists at St. Jude Children's Research Hospital have shown that a drug inhibiting ...
Mar 6, 2024
0
0